Is Surgery Really No Better Than Medication for GERD? Revisiting a 20-Year-Old Debate

It is worth revisiting, because a lot has changed in the two decades since. Some of it came from the very same author.

The Case the 2003 Review Made

The review compared medical and surgical treatment for GERD across five factors: healing, prevention of complications, safety, convenience, and cost. Its main points were straightforward. A large VA trial had found no significant difference between medical and surgical patients in long-term well-being or in preventing complications like strictures. Acid-suppressing medications were described as remarkably safe. Surgical mortality was cited at roughly 1 in 600 patients, based on a review of laparoscopic Nissen fundoplication series available at the time. And a Swedish population study raised the question of whether fundoplication actually prevented esophageal cancer at all, since surgical patients in that cohort had a higher relative risk of the disease than medically treated patients.

Taken together, the review’s message was that surgery for a benign, well-controlled condition was hard to justify unless a patient specifically valued not taking a daily pill.

What the Same Author Found 16 Years Later

Here is the part that gets left out when this review is cited today. The author of that 2003 paper, Dr. Stuart Spechler, went on to lead a randomized trial published in the New England Journal of Medicine in 2019, comparing surgery with medical therapy in patients whose heartburn had not responded to PPI treatment.

The key detail is how those patients were chosen. Before randomization, every patient underwent endoscopy, esophageal biopsy, manometry, and impedance-pH testing to confirm that their symptoms were actually caused by reflux, rather than a functional disorder or something else entirely. Once that careful selection was done, the results were not close. Surgery succeeded in 67 percent of patients, compared with 28 percent on active medical therapy and 12 percent on placebo-level medical therapy.

In other words, when reflux is properly confirmed as the cause of a patient’s symptoms, rather than assumed, surgery outperforms medication by a wide margin. This is precisely why I perform every diagnostic study myself before recommending any treatment, including endoscopy, manometry, pH-impedance testing, and an upper GI series. Selection is the difference between a good surgical outcome and a disappointing one.

Surgical Safety Numbers Have Also Changed

The 1-in-600 mortality figure cited in 2003 came from a review of just over 2,000 patients treated at select expert centers in the 1990s. A far larger, nationwide Swedish cohort study of nearly 9,000 working-age patients who underwent laparoscopic fundoplication between 1997 and 2013 found a 90-day all-cause mortality rate of 0.08 percent, with only one death directly related to surgery in the entire cohort, a rate of about 1 in 9,000.

Surgical technique, patient selection, and perioperative care have all improved substantially since the early days of laparoscopic fundoplication. In my own practice, hiatal hernia repair has a recurrence rate under 1 percent.

Medications Are Not as Risk-Free as They Once Seemed

The 2003 review described PPIs as remarkably safe, and for most patients using them short-term, that remains true. But long-term PPI use has come under closer scrutiny in the years since. A 2025 systematic review summarized associations reported in the literature between prolonged PPI use and chronic kidney disease, bone fracture, low magnesium levels, vitamin B12 deficiency, Clostridium difficile infection, and, in some studies, dementia.

It is important to be precise about what this evidence shows. Most of these findings come from observational studies, which can show an association without proving that PPIs directly cause the problem. Still, the picture is more complicated than the “remarkably safe” framing from 2003, and it is a conversation every patient facing years or decades of daily medication deserves to have.

Does Modern Surgery Actually Last?

The 2003 review raised a fair question about durability, noting that many surgical patients in the original VA trial eventually returned to taking antireflux medication. That concern was not unfounded at the time. But newer data on modern laparoscopic technique paints a more favorable picture. One series following patients for a mean of 11 years after laparoscopic Nissen fundoplication found that the overwhelming majority remained symptom-free or significantly improved, with heartburn and regurgitation showing the most durable improvement.

To be fair, not every large trial has told the same story. A well-designed European trial comparing modern laparoscopic surgery with optimized esomeprazole therapy found a slightly higher 5-year remission rate with medication than with surgery on its primary endpoint, though surgery performed better on measures specific to regurgitation and acid control. This is exactly why the conversation should never be “surgery versus medication” as a blanket rule. It should be about which treatment fits a specific patient’s confirmed diagnosis and goals.

The Real Lesson, Twenty Years Later

The 2003 review was not wrong about everything. It correctly warned against unproven, poorly studied procedures rushed into practice without solid trial data, a caution that still applies to any new antireflux technology today. But its broader conclusion, that surgery offers no real advantage over medication, has not held up well against two more decades of evidence, including a trial led by the same author who wrote it.

What has held up is the underlying principle. Any decision between medical and surgical treatment for GERD should rest on a confirmed diagnosis, not an assumption. That means doing the full workup before recommending an operation, and being honest with patients about what the modern data actually shows on both sides.

Key Clinical Points

• A widely cited 2003 review argued surgery had no clear advantage over medication for GERD, based largely on data available before modern patient selection tools were standard.
• A 2019 randomized trial, led by the same author, found surgery significantly outperformed medication once reflux was confirmed with manometry and pH-impedance testing.
• A large modern cohort study found surgical mortality far lower than the figure cited in 2003, at roughly 1 in 9,000 rather than 1 in 600.
• Long-term PPI use has since been associated with kidney, bone, and nutritional risks that were not part of the 2003 safety discussion.
• Dr. Darido performs the complete diagnostic workup himself, including endoscopy, manometry, pH-impedance testing, and upper GI studies, before recommending surgery.

Selected References

• Spechler SJ. Medical or invasive therapy for GERD: an acidulous analysis. Clin Gastroenterol Hepatol. 2003;1:81-88.
• Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381:1513-1523.
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305:1969-1977.
• Mortality from laparoscopic antireflux surgery in a nationwide cohort of the working-age population. Br J Surg. 2016.
• Chaudhry M, Elahi M, Bukhari SHA, et al. Long-term proton pump inhibitor use and the risk of kidney disease, dementia, and fractures: a systematic review. Cureus. 2025.